10/15/2026

Janusmed sex and gender

Janusmed sex and gender – naltrexone hydrochloride

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Naltrexone

Naltrexone

Class : A

Show all info

Print

Contact us

  1. Global Burden of Disease Sex Differences Visualization. Seattle, WA: Institute for Health Metrics and Evaluation (IHME). 2023 [cited 2026-05-05.]

  2. Statistikdatabas för diagnoser. Stockholm: Socialstyrelsen. 2024 [cited 2026-05-05.]

  3. Statistikdatabas för dödsorsaker. Stockholm: Socialstyrelsen. 2024 [cited 2026-05-05.]

  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - VIVTROL (naltrexone). Drugs@FDA [www]. [updated 2006-04-13, cited 2016-04-01].

  5. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-17.

  6. Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34:1803-12.

  7. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-62.

  8. Morley KC, Teesson M, Sannibale C, Baillie A, Haber PS. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial. Alcohol Alcohol. 2010;45:520-6.

  9. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-9.

  10. Kiefer F, Jahn H, Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry. 2005;38:184-6.

  11. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-25.

  12. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-13.

  13. Food and Drug Administration (FDA). Medical review - Contrave (naltrexone / bupropion). Drugs@FDA [www]. [updated 2014-10-09, cited 2026-05-05].

  14. Cataldi M, Muscogiuri G, Savastano S, et al. Gender-related issues in the pharmacology of new anti-obesity drugs. Obes Rev. 2019;20(3):375-384.

  15. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, deWit H et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32:630-6.

  16. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Global Burden of Disease Sex Differences Visualization. Seattle, WA: Institute for Health Metrics and Evaluation (IHME). 2023 [cited 2026-05-05.]
  2. Statistikdatabas för diagnoser. Stockholm: Socialstyrelsen. 2024 [cited 2026-05-05.]
  3. Statistikdatabas för dödsorsaker. Stockholm: Socialstyrelsen. 2024 [cited 2026-05-05.]
  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - VIVTROL (naltrexone). Drugs@FDA [www]. [updated 2006-04-13, cited 2016-04-01].
  5. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-17.
  6. Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34:1803-12.
  7. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-62.
  8. Morley KC, Teesson M, Sannibale C, Baillie A, Haber PS. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial. Alcohol Alcohol. 2010;45:520-6.
  9. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-9.
  10. Kiefer F, Jahn H, Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry. 2005;38:184-6.
  11. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-25.
  12. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-13.
  13. Food and Drug Administration (FDA). Medical review - Contrave (naltrexone / bupropion). Drugs@FDA [www]. [updated 2014-10-09, cited 2026-05-05].
  14. Cataldi M, Muscogiuri G, Savastano S, et al. Gender-related issues in the pharmacology of new anti-obesity drugs. Obes Rev. 2019;20(3):375-384.
  15. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, deWit H et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32:630-6.
  16. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]